pediapharm Chef de file pharmaceutique en pédiatrie au Canada

Canada's Leading Pediatric Pharmaceutical Company

What's new

Pediapharm Receives Health Canada Approval for Rupatadine

Read more >

Pediapharm Announces Annual Audited Financial Results-Operating Profit of $1.9 Million in Q4 and Improvement of $3.7 Million in Annual Operating Loss

Read more >

Pediapharm Receives FDA Supplement Approval Regarding Naproxen Suspension in the US, Receives Additional US$2 Million from Atnahs Pharma

Read more >

Products

Stock – PDP.V